Clearmind Medicine Inc. (CMND) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Clearmind Medicine Inc.

    NASDAQ: CMND · Real-Time Price · USD
    1.05
    -0.01 (-0.94%)
    At close: Sep 26, 2025, 3:59 PM
    1.05
    0.00%
    After-hours: Sep 26, 2025, 07:33 PM EDT

    Clearmind Medicine Income Statement

    Financials in USD. Fiscal year is November - October.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Oct 31, 2024 Oct 31, 2023 Oct 31, 2022 Oct 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a 56.34K 113.38K 2.57K
    Gross Profit
    		 -26.7K -56.34K -113.38K -2.57K
    Operating Income
    		 -8M -8.74M -8.53M -3.68M
    Interest Income
    		 271.22K 57.97K n/a n/a
    Pretax Income
    		 -4.88M -11.93M -9.37M -3.72M
    Net Income
    		 -5.25M -11.96M -9.41M -3.72M
    Selling & General & Admin
    		 4.35M 6.6M 5.43M 3.03M
    Research & Development
    		 1.38M 2.14M 2.98M 646.49K
    Other Expenses
    		 2.27M n/a 113.38K n/a
    Operating Expenses
    		 8M 8.74M 8.53M 3.68M
    Interest Expense
    		 36.16K n/a 19.68K n/a
    Selling & Marketing Expenses
    		 1.09M n/a n/a n/a
    Cost & Expenses
    		 8M 8.74M 8.53M 3.68M
    Income Tax Expense
    		 377.97K 24.09K 40.75K n/a
    Shares Outstanding (Basic)
    		 4.27M 2.02M 433.34K 309.11K
    Shares Outstanding (Diluted)
    		 4.27M 2.02M 433.34K 309.11K
    EPS (Basic)
    		 -1.69 -42.58 -168.61 -120.3
    EPS (Diluted)
    		 -1.69 -42.58 -217.2 -120.3
    EBITDA
    		 -7.98M -8.71M -8.49M -3.67M
    EBIT
    		 -8M -8.74M -8.52M -3.69M
    Depreciation & Amortization
    		 16.78K 30.69K 30.52K 2.57K

    Add to Watchlist